J B Chemicals & Pharmaceuticals Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/3ecefuk1bozantfbrota173u.pdf

Key Takeaways


Domestic Formulations: The Volume-Led Engine

Kunal Khanna: "Yes, it's a reflection of, you know, not only our Ophthal but even our overall India business and even Ophthal is absolutely volume driven. See, because beyond a certain point, there is no real opportunity for us to take price growth beyond 7 to 8%, right? So, it's volume driven."

Cilacar Franchise & Cardiology Strategy

Nikhil Chopra: "So, we have a whole range of portfolio and this is not only that we are going and talking in the clinic and generating value, but overall the objective is how to reduce the burden of disease for the patients who are suffering from hypertension and comorbidities. So, that is the task that we have taken. That is why you see the entire differential that we as a company bring on the table as compared to other companies."

Ophthalmology: Early-Stage Volume Ramp


CDMO: The Second Growth Pillar


International Formulations: Mixed, with Q4 Promise


Margins & Capital Allocation

Nikhil Chopra: "You always will see Rahul, us being, what guidance we have been giving, of 26 to 28% probably we will be ending the year on a higher note on the higher side of the guidance... At the right time, we will be more than happy to revise our guidelines, which touch wood should be on the upward trajectory only."

Guidance & Commitments

CommitmentSpecificsTimeline
Operating EBITDA margin26% to 28% range; ending FY25 on the higher side; open to upward revisionFY25 exit / "at the right time"
India business growthMid-teens growth backed by strong volume growthOngoing (Q4 onwards includes ophthalmology base)
International business growthDouble-digit growth in Q4; high single-digit to double-digit medium termQ4 FY25 / medium term
CDMO business growthMid-teens growth; strong Q4 order bookShort to medium term
Ophthalmology SKU launchesOne or two new SKUs added every quarterNext 6-8 months
Ophthalmology margin improvementGross margin from ~20% to 70%, adding 200 bps to overall EBITDAVague timeline
CDMO big projects4-5 big global projects kicking in; CAPEX already placed18-24 months visibility
Brand pipeline10-12 brands inching toward ₹50 cr run rateNext 2-3 years
Cilacar-T ambitionBecome a ₹1,000 cr productForeseeable future
India + CDMO revenue contributionMove from 72% to 80% of total revenueShort to medium term
Debt-free statusAll loans paid offImminent

Key Metrics

MetricQ3 FY25
Revenue₹963 cr, +14% YoY
Operating EBITDA₹270 cr, +15% YoY
Operating EBITDA margin28.1%, improved from 27.6% in Q3 FY24 (per an analyst's math)
Net profit₹162 cr, +22% YoY
Gross margin67.1%, vs 67.6% in Q3 FY24
Gross margin ex-ophthalmologyImproved 160 bps YoY and at YTD level
Domestic business revenue₹566 cr, +22% YoY
Domestic business growth vs IPM12% YoY vs IPM growth of 8%
Domestic volume growth ex-ophthalmology7% for Q3 FY25, 6% for 9-month FY25
International business revenue₹397 cr, +4% YoY
CDMO business revenue₹118 cr, +33% YoY
Finance costs₹3 cr, down from ₹12 cr in Q3 FY24
Depreciation₹42 cr, same as previous quarter
Gross debt₹54 cr as of 30th Dec 2024
Net cash₹516 cr as of 30th Dec 2024
ESOP cost FY25 full-year expected₹56 cr, with ₹16 cr in Q4 FY25
MTM forex loss₹4 cr, primarily from ruble depreciation
Russia constant currency growth-5% vs -8% reported
Ophthalmology portfolio growth28% plus vs market growth of close to 9%
Top 5 domestic brands contribution60-65% of overall India business, down from over 75% in FY20
Brands with revenue >₹25 cr25 brands, up from 6 in December 2020
Azmarda monthly unit trend~130,000 units per month, up from 95-100,000 five to six months ago
Sporlac revenueMore than ₹120 cr (IQVIA MAT reflection)
EBITDA margin guidance26% to 28%, expected to end FY25 close to 28%
India + CDMO revenue contribution72% of total revenue, up from 50% four years ago